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Abstract
Introduction: High maternal HIV incidence contributes substantially to mother-to-child HIV transmission (MTCT) in some set-
tings. Since 2006, HIV retesting during the third trimester and breastfeeding has been recommended by the World Health
Organization in higher prevalence (≥5%) settings to reduce MTCT. However, many countries lack clarity on when and how
often to retest pregnant and postpartum women to optimize resources and service delivery. We reviewed and characterized
national guidelines on maternal retesting based on timing and frequency.
Methods: We identified 52 countries to represent variations in HIV prevalence, geography, and MTCT priority and searched
available national MTCT, HIV testing and HIV treatment policies published between 2007 and 2017 for recommendations on
retesting during pregnancy, labour/delivery and postpartum. Recommended retesting frequency and timing was extracted.
Country HIV prevalence was classified as: very low (<1%), low (1% to 5%), intermediate (>5 to <15%) and high (≥15%).
Women with unknown HIV status at delivery/postpartum were included in retesting guidelines.
Results and discussion: Overall, policies from 49 countries were identified; 51% from 2015 or later and most (n = 25) were
from Africa. Four countries were high HIV prevalence, seven intermediate, sixteen low and twenty-two very low. Most
(n = 31) had guidance on universal voluntary opt-out HIV testing at the first antenatal care (ANC) visit. Beyond the first ANC
visit, the majority (78%, n = 38) had guidance on retesting; 22 recommended retesting all women with unknown/negative sta-
tus, five only if unknown HIV status, three in pregnancy based on risk and eight combining these approaches. Retesting was
universally recommended during pregnancy, labour/delivery, and postpartum for all high prevalence settings and four of seven
intermediate prevalence settings. Five UNAIDS priority countries for EMTCT with low/very low HIV prevalence, but high/in-
termediate MTCT, had no guidance on retesting.
Conclusions: Retesting guidelines for pregnant and postpartum women were ubiquitous in high prevalence countries and
defined in some intermediate prevalence countries, but absent in some low HIV prevalence countries with high MTCT. Coun-
tries may require additional guidance on how to optimize maternal HIV testing and whether to prioritize retesting efforts or
discontinue universal retesting based on HIV incidence. Research is needed to assess country-level guideline implementation
and impact.
Keywords: HIV; mother-to-child transmission; retesting; incidence; prevention of mother-to-child HIV transmission
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1 | INTRODUCTION
Maternal HIV testing and treatment is the cornerstone of pre-
vention of mother-to-child HIV transmission (PMTCT) pro-
grammes, and has helped to prevent over two million
paediatric HIV infections since 2000 [1]. Despite implementa-
tion of highly effective prevention interventions, in 2017, an
estimated 180,000 new paediatric HIV infections occurred;
the vast majority (90%) in sub-Saharan Africa [1]. High (>3
per 100 person-years) maternal HIV incidence (during both
pregnancy and breastfeeding) contributes substantially to
mother-to-child HIV transmission (MTCT) in sub-Saharan
Africa [2-12], accounting for nearly half of all paediatric HIV
infections in some high prevalence settings [13,14]. Thus,
efforts to move towards elimination of mother-to-child HIV
transmission (EMTCT) will increasingly need to focus on
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prevention, and early identification and treatment of HIV
infections acquired during pregnancy and breastfeeding to
achieve viral suppression.
Identification of newly HIV-infected pregnant and postpar-
tum women will be important to achieve the UNAIDS
90:90:90 goals [15]. While efforts towards EMTCT encompass
both high and low prevalence settings, timely identification
and treatment of HIV-infected pregnant women are critical
components of all successful programmes. As a result, most
countries have implemented maternal HIV testing as a routine
component of antenatal care (ANC) services to maximize pre-
vention potential through early maternal treatment and infant
prophylaxis [16]. However, strategies to detect HIV infections
among women who miss ANC testing or initially test HIV neg-
ative during pregnancy and acquire HIV either later in preg-
nancy or while breastfeeding are also needed. Women who
have difficulty accessing healthcare services, or were not
offered HIV testing during ANC due to lack of counselling or
HIV test kit stock-outs, have increased risks of not knowing
their HIV status [17,18]. Retesting during pregnancy/postpar-
tum has been shown to be an effective strategy to detect inci-
dent maternal infections [3,4,9], resulting in low MTCT
transmission rates in one study conducted in Kenya [3].
Since 2006, the World Health Organization (WHO) has rec-
ommended retesting pregnant women for HIV in countries
with high prevalence during the third trimester, and since
2015 has expanded that guidance to include retesting during
pregnancy, at labour/delivery and/or in the postpartum period
[19-21]. In low prevalence countries and countries with con-
centrated epidemics, maternal retesting is recommended for
women at high risk in serodiscordant relationships or mem-
bers of key populations [19-23]. The lack of clarity on the
specific frequency and time points to conduct retesting during
pregnancy and the postpartum period can create confusion
for programme implementers about when to offer retesting,
contributing to suboptimal implementation. In contrast, other
programmes may be offering retesting more frequently than
needed, and wasting limited public health resources on unnec-
essary retesting [22,24,25]. Countries need additional data on
the impact of retesting during pregnancy, labour/delivery and
postpartum to appropriately allocate HIV resources, including
allocation within PMTCT programmes. Many countries have
national guidelines on maternal HIV retesting, but similarities
and differences between guidelines based on geographic
region, HIV prevalence, MTCT rates or country-level priorities
for EMTCT have not been previously described.
We reviewed national HIV guidelines on HIV testing for
pregnant and postpartum women to characterize current rec-
ommendations for the timing and frequency of maternal HIV
retesting. In addition, we compared retesting strategies by
geographic region, national HIV prevalence and MTCT rates.
2 | METHODS
2.1 | Guideline selection, review process and
translations
We conducted a standardized review of individual country
policies on maternal HIV retesting during pregnancy and post-
partum. A total of 52 countries were selected to review, rep-
resenting a range of HIV prevalence, geographic regions and
all 23 UNAIDS priority countries for EMTCT [26], which col-
lectively account for the majority of HIV infections among
pregnant women. UNAIDS has prioritized countries for
EMTCT due to the high number of HIV infections among
women, children and adolescents [26]. Countries with avail-
able guidelines on PMTCT, antiretroviral treatment (ART),
and/or HIV testing from 2007 (following initial WHO recom-
mendations) or later were included in the review. Any country
guidelines on HIV self-testing or pre-exposure prophylaxis
(PrEP) were also reviewed when available. Guidelines were
requested directly from country contacts via email if they
were not previously identified for inclusion of a prior WHO
HIV testing policy review or available through online searches
[27]. We used the summary of the guidelines provided by
country contacts if they were able to provide documentation
of their guidelines along with the English summary. In addition,
country contacts who confirmed that no retesting guidelines
exist were included in our review and countries were classi-
fied as not having retesting guidelines. Guidelines published in
2012 or later were prioritized for review, and countries were
contacted to request updated guidelines if publication dates
were between 2007 and 2011. For countries with multiple
available guidelines, we used the most recent published guide-
line, or the guideline with the most complete information on
maternal HIV testing policies.
Guidelines were reviewed for sections relevant to HIV test-
ing during pregnancy and postpartum, and using a key word
search for the following terms: pregnancy, antenatal, labor/
labour, delivery, postpartum, postnatal, breastfeeding and/or
lactating. A primary reviewer extracted data from the guideli-
nes into a standardized extraction tool; a secondary reviewer
repeated this process and highlighted any discrepancies with
the primary reviewer (Data S1). Discrepancies were discussed
and resolved between primary and secondary reviewers, or
with a third reviewer, if needed.
No country guidelines were excluded from the current
review based on language. Non-English languages included
Chinese, Portuguese, French, Spanish and Ukrainian. All non-
English guidelines (except from Ukraine and Cuba) were
reviewed by an independent translator using only key word
searches; text related to HIV testing and the key word(s)
identified was extracted into a standardized form (referencing
the page number with original text) and translated into Eng-
lish. Translations of guidelines from Ukraine and Cuba were
summarized by a country contact. A secondary reviewer fluent
in the original language also reviewed the guidelines and
translated text to ensure all references to maternal HIV test-
ing were extracted and accurately translated.
Data extracted from country guidelines included initial ANC
HIV testing; guidelines for HIV retesting during pregnancy,
labour/delivery and postpartum/breastfeeding; timing and eli-
gibility for HIV retesting; and frequency of retesting. Since
women who missed initial HIV testing during pregnancy for
any reason (e.g. test kit stock-out, declined test and/or did not
access ANC) would programmatically be captured in retesting
programmes, we extracted recommendations on HIV testing
for women who received or missed initial HIV testing during
pregnancy and classified this as maternal retesting.
Guidelines were classified as having any guidance on mater-
nal HIV retesting (yes/no). Countries with general population
policies for retesting that were not specific to pregnant or
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postpartum women were classified as not having guidance on
maternal HIV retesting. Countries with maternal HIV retesting
guidelines were classified based on their approach to retesting
as: (1) universal if testing recommendations apply to all preg-
nant and/or postpartum women; (2) targeted if testing recom-
mendations apply to pregnant and/or postpartum women
based on individual- or population-level risk factors; (3) only if
unknown if testing recommendations are only for pregnant/
postpartum women without documented HIV test results from
earlier ANC visits; (4) combination if more than one approach
was recommended during pregnancy and postpartum (univer-
sal, targeted and/or only if unknown approaches; Table 1).
Individual or population-level risk factors for targeted retest-
ing recommendations included belonging to a group with high
risk of HIV exposure, being in an HIV serodiscordant relation-
ship, or residing in a high HIV prevalence setting. Universal,
combination, or only if unknown approaches to HIV testing
were all considered population-level approaches to retesting
(vs. targeted only approaches only). Approaches to maternal
HIV retesting were stratified based on the time period (gen-
eral peripartum, pregnancy, labour/delivery and/or postpar-
tum/breastfeeding) and frequency (1 or >1 retest per time
period) of maternal retesting.
Countries were classified according to WHO regions (Amer-
icas, Africa, South-East Asia, Europe, Eastern Mediterranean
or Western Pacific). Country-level HIV prevalence in the gen-
eral population data was abstracted from 2016 UNAIDS esti-
mates if available, or other published estimates from country
guidelines. Estimated rates of MTCT (including the breast-
feeding period up to 36 months) per country were obtained
from the 2016 UNAIDS Spectrum model estimates or other
published sources. We developed categories for both HIV
prevalence and MTCT as follows: very low (<1%), low (1% to
5%), intermediate (>5% to <15%) and high (≥15%) based on
previous work by Ishikawa and colleagues [28].
3 | RESULTS AND DISCUSSION
3.1 | Country characteristics
Among 52 countries selected for the review, 49 countries
with available guideline documents were successfully retrieved
(including two countries who confirmed the absence of mater-
nal retesting guidelines) and included in the review. Three
countries with unavailable guidelines and no communication
from countries about retesting included: Belarus, Burkina Faso
and Comoros. Most (n = 25) countries were from the African
Region, followed by the Eastern-Mediterranean (n = 7), Amer-
icas (n = 6), South-East Asia (n = 5), Western-Pacific (n = 4)
and European (n = 2) regions. The review included four high
prevalence (≥15%), seven intermediate prevalence (>5 -
<15%), sixteen low prevalence (1% to 5%) and twenty-two
very low prevalence (<1%) countries. Twenty-three (47%)
countries are classified as UNAIDS priority countries for
EMTCT. English language guidelines were available for full
text review for 34 countries; 11 countries with non-English
guidelines had limited key word text review after translation.
In addition, two country contacts provided a summary of
guidelines translated into English (Ukraine and Cuba) and two
country contacts confirmed a lack of retesting maternal guide-
lines (Morocco and Vietnam).
3.2 | Overview of current maternal retesting
guidelines
Most countries had guidance specifying universal voluntary
opt-out HIV testing at the first ANC visit (n = 31). Beyond
the initial HIV test, the majority of countries (n = 38) had
guidance on maternal HIV retesting (Figure 1). Eleven coun-
tries, including five priority EMTCT countries, were classified
as not having maternal retesting guidelines: four countries
with low HIV prevalence (Burundi, Chad, Cote d’Ivoire, and
Trinidad and Tobago), and seven countries with very low HIV
prevalence (Australia, Democratic Republic of the Congo,
Indonesia, Morocco, Philippines, Somalia and Vietnam).
Three countries use a targeted approach for maternal
retesting. El Salvador recommends retesting during each tri-
mester of pregnancy and at labour/delivery if women have a
high risk of HIV acquisition, including members of HIV
serodiscordant couples; Pakistan recommends retesting for
pregnant women with known or continued HIV exposure; and
Sierra Leone recommends retesting for pregnant women 6 to
12 weeks after the initial test in case they were tested during
the window period of detection or if they had an additional
exposure to HIV.
The majority (n = 35) of countries recommend a popula-
tion-level testing approach, most commonly a universal
approach (n = 22, 58%). Eight countries (21%) followed a
combination approach, employing both universal and targeted
approaches. In five very low HIV prevalence countries (Afgha-
nistan, Cambodia, Egypt, Nepal and Sudan), maternal retesting
is not targeted based on individual- or population-based HIV
risk but only offered if the woman’s status is unknown, that is,
initial ANC HIV testing was not conducted.
In two low HIV prevalence countries, Ethiopia and Tanza-
nia, maternal retesting is advised but guidelines lack speci-
ficity on the frequency and timing of retesting. Table 2
presents an overview of the testing approach, frequency and
recommended time points for maternal retesting by country
among the 38 countries that recommend any maternal HIV
retesting. Among countries recommending retesting during
pregnancy and/or postpartum, the most commonly targeted
time points are during the third trimester of pregnancy, at
Table 1. Definitions for Country approaches to maternal HIV
retesting
Definition of
approach
Populations recommended to receive
maternal HIV retesting
Universal All pregnant/postpartum women
Targeteda Dependent on risk behaviour, partner status,
and/or high HIV prevalence
Only if unknown Only if maternal HIV status is unknown/no
previous HIV test result documented
Combination Combination of universal, targeted, and/or only
if unknown approaches, depending on
peripartum status
aIndividual-level approach.
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six weeks postpartum and/or every three months during
breastfeeding.
3.3 | Recommended timing and frequency of HIV
retesting
Among all 49 countries reviewed, the majority (n = 31, 63%)
recommend retesting during pregnancy. Twenty-three coun-
tries recommend a universal testing approach, including 1 ret-
est (n = 12, 24%) or >1 retest (n = 11, 22%); and eight
countries (16%) recommend maternal retesting based on tar-
geted risk factors, unknown status or a combination of factors
(Figure 2a). Most countries (n = 27, 55%) recommend retest-
ing during labour/delivery. Sixteen countries (33%) recom-
mend a universal HIV testing strategy for all women during
labour/delivery and 11 (22%) recommend maternal retesting
based on targeted risk factors, unknown status or a combina-
tion of factors (Figure 2b). Similarly, one third of countries
(n = 17, 35%) recommend maternal retesting in the postpar-
tum period. Eleven countries (22%) recommend a universal
HIV testing strategy for all postpartum women at more than
one time point, 1 (2%) recommend retesting once during the
postpartum period, and four countries (10%) recommend
maternal retesting based on targeted risk factors or unknown
status (Figure 2c).
Among the 33 countries that had recommendations on the
timing of retesting during the paripartum period, 15 (45%)
recommend retesting during pregnancy, labour and delivery,
and postpartum; 5 (15%) in pregnancy only; 4 (12%) at labour
and delivery only; 1 (3%) only postpartum; 7 (21%) in preg-
nancy and at labour and delivery; and 1 (3%) in pregnancy
and postpartum. Eswatini (formerly Swaziland) and South
Africa, where HIV prevalence is 27% and 18.9% respectively,
have guidelines recommending some of the most frequent
maternal retesting. Eswatini recommends retesting eight
weeks after the initial test, at each subsequent ANC visit, dur-
ing labour/delivery, at six weeks postpartum, and every clinic
visit during breastfeeding. Similarly, in South Africa retesting is
recommended at each ANC visit, during labour/delivery and
every three months until cessation of breastfeeding. As South
Africa is moving to ANC visits monthly until the third trime-
ster, and bi-weekly during the third trimester, this could con-
stitute eight to ten retests during pregnancy for women
depending if ANC is initiated early, together with our retests
during delivery/postpartum, for a total of 14 tests.
There was a clear relationship between HIV prevalence and
retesting guidance, with recommendations to conduct retest-
ing more frequently as country HIV prevalence increased at
each time point (pregnancy, labour/delivery and postpartum)
(Figure 3). Retesting guidelines were ubiquitous in all four
high HIV prevalence countries and four of seven intermediate
prevalence countries, with a universal approach to retesting
recommended at multiple time points during pregnancy,
labour/delivery and in the postpartum period. The majority
49 Countries with guidelines
Guidelines recommend any retesting during 
pregnancy and/or postpartum
11 No* (22%)
38 Yes (78%)
27 Labor/delivery** 31 Pregnancy** 17 Postpartum** 2 General peripartum
3 Targeted 
approach only
(8%)
35 Population-level approaches (92%)
ï 22 Universal (63%)
ï 8 Combination (23%)
ï 5 Only if unknown status (14%)
Approach to testing
16 Universal  (59%)
11 Specific testing (41%)
ï 1 Targeted (4%)
ï 2 Combined (8%)
ï 8 Only if unknown status (30%)
Approach to testing
23 Universal  (74%)
ï 11 >1 retest (35%)
ï 12 1 retest (39%)
8 Specific testing (26%)
ï 6 Targeted (20%)
ï 2 Only if unknown status (6%)
Approach to testing
12 Universal (71%)
ï 11 >1 retest (65%)
ï 1 1 retest (6%)
5 Specific testing (29%)
ï 1 Targeted (6%)
ï 4 Only if unknown status (24%)
Figure 1. Maternal HIV retesting recommendations in 49 HIV policies.
*Includes 1 country (Indonesia) where guidance follows general population approach only. **Not mutually exclusive. Universal; retesting recom-
mended for all pregnant and/or postpartum women. Targeted; retesting recommended based on individual or population-level risk factors. Only if
unknown; retesting recommended only if maternal HIV status is not previously documented. Combination; retesting recommended using a combi-
nation of universal, targeted and unknown approaches depending on the peripartum stage. General peripartum includes Ethiopia and Tanzania.
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Figure 2. Maternal HIV retesting approaches among 49 countries, by HIV prevalence.
HIV prevalence in general population defined as high (≥15%), intermediate (>5% to <15%), low (1% to 5%%) or very low (<1%). Universal testing
for all pregnant women or all postpartum women is categorized as 1 or >1 retest. Specific testing includes: targeted guidelines based on risk, only
if unknown, or combination approaches. (a) During pregnancy. (b) During labour/delivery. (c) During the postpartum period.
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(63%, n = 10) of low HIV prevalence settings did have retest-
ing recommendations; 31% (n = 5) recommended retesting
during pregnancy, labour/delivery and postpartum; 19% only
during pregnancy, 13% during pregnancy and labour/delivery.
While most (68%, n = 15) countries in very low HIV preva-
lence settings had recommendations for retesting, there was
substantial heterogeneity in the approach to testing between
countries. Only 14% (n = 3) of very low HIV prevalence set-
tings had any guidance on retesting in the postpartum period.
Data on MTCT rates from 2016 were available for 44 coun-
tries included in the policy review. Among 33 of these coun-
tries with low/very low HIV prevalence, 29 had high/
intermediate MTCT rates of which 38% (n = 11) did not have
any recommendations for maternal HIV retesting during preg-
nancy, labour and delivery, or in the postpartum period (Fig-
ure 4) despite seven being EMTCT priority countries. Low/
very low HIV prevalence countries with high/intermediate
MTCT rates who lack maternal retesting guidance may con-
sider recommending a maternal HIV retest to reduce MTCT
rates attributable to incident maternal infections, particularly
for women who may have an elevated risk of HIV acquisition.
In contrast, among 11 high/intermediate HIV prevalence coun-
tries, four countries (all were EMTCT priority countries) had
low/very low MTCT rates and 100% recommended retesting
at least twice during pregnancy and postpartum (at least two
total retests). Despite the high/intermediate HIV prevalence
of these countries, increasing the number of times women are
retested may have limited utility in these settings and may
indicate that pregnant and postpartum women are being over-
tested. Reducing or eliminating maternal retesting in these
settings may be appropriate, allowing maternal retesting
resources to be reallocated towards other HIV treatment and
prevention strategies. Mathematical models to assess the
cost-effectiveness of maternal retesting in countries with low
HIV prevalence or low MTCT rates are needed to help deter-
mine the public health and economic impact of modifying
retesting policies in specific settings.
Our review was subject to some limitations. We were
unable to obtain guidelines for three countries and may not
have the most recent versions of retesting guidelines for some
countries. National programmes may be in the process of
guideline revision, or implementing practices that have not yet
been incorporated into written national policies, and our
results would not reflect these changes. Furthermore, we did
not summarize national policies in countries with concentrated
epidemics in key populations due to the low frequency of
these types of policies.
Written guidelines supporting maternal retesting for HIV
are important to detect new maternal HIV infection and move
towards EMTCT. However, it is also important to measure
guideline implementation and assess how guidelines translate
into public health practice. Several barriers to HIV testing
have previously been described, including difficulty accessing
HIV counselling and testing services, stigma, test kit stock-
outs, inaccurate perceptions of HIV risk and fear of positive
test results [69]. While these barriers also apply to HIV
retesting, there are additional barriers unique to retesting.
Healthcare workers may have difficulty tracking guidelines for
different populations, or may not be aware that guidance is
dependent on individual- or population-level characteristics. In
addition, vague language in guidelines about who and when to
retest can result in missed opportunities to offer peripartum
women retesting. Prior studies in sub-Saharan Africa suggest
that only ~30% of pregnant women eligible for retesting who
returned to the clinic received a test [70,71]. In contrast,
implementing retesting guidelines designed for the general
population can also create confusion for healthcare workers
to retest pregnant and postpartum women. While attendance
at maternal and child health (MCH) clinics for ANC, postnatal
care and infant immunizations is high in many settings, the
MCH visit schedule does not follow regular intervals making it
more challenging to align calendar interval recommendations
for retesting (e.g. every six months) with MCH visits. Further-
more, in many settings the only time during the postpartum
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Figure 3. Frequency of maternal HIV retesting among 49 countries, by HIV prevalence.
All includes recommendations during pregnancy, labor/delivery, and the postpartum period. HIV prevalence in general population defined as high
(≥15%), intermediate (>5% to <15%), low (1% to 5%) or very low (<1%).
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period where maternal health is specifically assessed is at four
to six weeks postpartum; all other visits are related to infant
health.
Use of HIV self-tests (HIVSTs) may be one approach to
overcome challenges with clinic-based retesting for pregnant
and postpartum women, as well as testing partners. Reaching
partners of pregnant and postpartum women through partner
HIV testing and partner notification services remain crucial to
HIV testing approaches and efforts to reduce new maternal
infections. Some studies have found high acceptability of oral
HIVST among male partners given test kits by pregnant or
postpartum partners through a “secondary distribution” strat-
egy from MCH clinics [72,73]. This approach relies on
instructing women how to use HIVST, including how to inter-
pret results and referral procedures for confirmatory testing
if initial HIVST results are positive. However, recent analyses
continue to show that both policies to support partner HIV
testing and partner notification, and implementation of these
activities, are lacking [74]. In contrast, evaluations of HIVST to
support maternal HIV retesting have not been conducted. It is
possible that home-based HIVSTs, using either saliva or blood,
could be offered as an additional, available approach to over-
come some of the barriers to clinic-based blood HIV testing
and increase retesting rates among women who may other-
wise fail to be tested again. Alternatively, clinic-based HIVST
could provide an opportunity to reduce healthcare system
burden to conduct maternal retesting for triage, while also
offering women privacy and confidentiality outside of their
homes. In our review, we systematically searched for guidance
on HIVST, and while HIVST is available and recommended for
general population use in some countries, no country has yet
endorsed HIVST as a strategy to increase HIV retesting for
pregnant and postpartum women.
While improving HIV testing services is a critical component
of HIV prevention for pregnant and postpartum women, com-
plementary approaches including screening for sexually trans-
mitted infections (STIs), condom promotion and PrEP will also
be important to prevent new HIV infections in mothers and
infants. Recent WHO recommendations supporting PrEP use
during pregnancy and breastfeeding [75] following evidence of
PrEP safety [76,77] have led to pilot studies of PrEP imple-
mentation in ANC and PNC settings [78], but the impact PrEP
will have on reducing new maternal infections and MTCT is
unknown. Programmes should continue to support compre-
hensive HIV prevention strategies during pregnancy and post-
partum, including maternal retesting for HIV, based on
epidemic context.
4 | CONCLUSIONS
Maternal HIV retesting will increasingly be important to reach
EMTCT targets by detecting new maternal HIV infections and
achieving the 90:90:90 targets [15], including maternal viral
suppression through the linkage of newly diagnosed HIV-
infected women to HIV care and treatment. Globally, young
women of reproductive age have the highest risks of HIV
acquisition and strategies like maternal HIV retesting will also
be critical to interrupt heterosexual transmission as other pre-
vention interventions are rolled out. Countries with high HIV
prevalence universally recommended retesting pregnant and
postpartum women, but some low HIV prevalence countries
with high MTCT rates lack any guidance on maternal retest-
ing. Countries may find it helpful to receive guidance on
whether retesting should be offered to pregnant and/or post-
partum women, and the timing of retesting for countries that
view retesting as essential to capturing maternal incidence.
Furthermore, while wider implementation of PrEP during
pregnancy and postpartum over time may alter approaches
and necessity for maternal HIV retesting, it will be important
to understand context specific risks for maternal HIV acquisi-
tion and impact of retesting strategies before and after PrEP
implementation to guide policies and programmes. Studies
measuring the implementation of maternal retesting HIV
71%
100%
14%
14%
25%
38%
50%
70%
80%
90%
%52%57 7%
3%
17%
40%
50%
60%
nt
rie
s 
w
ith
 g
ui
de
lin
es
21% 25%
14%
10%
20%
30%
%
 C
ou
0%
High-int HIV prevalence/
High-int MTCT rate
(n = 7)
High-int HIV prevalence/
Low-very low MTCT rate
(n = 4)
Low-very low HIV prevalence/
High-int MTCT rate
(n = 28)
Low-very low HIV prevalence/
Low-very low MTCT rate
(n = 4)
All Pregnancy only Labor/delivery only Postpartum only Pregnancy & Labor/delivery Pregnancy & postpartum None
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and HIV prevalence classified as High-int (intermediate) if >5%; Low-very low if ≤5%. Five countries missing MTCT rate excluded from this
analysis.
Drake AL et al. Journal of the International AIDS Society 2019, 22:e25271
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25271/full | https://doi.org/10.1002/jia2.25271
9
guidelines, and impact of different testing approaches in vari-
ous epidemic settings are needed to maximize efforts to
detect and treat new maternal HIV infection, while balancing
costs of these approaches.
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